期刊
NATURE BIOTECHNOLOGY
卷 28, 期 6, 页码 573-579出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.1635
关键词
-
资金
- National Institute of Allergy and Infectious Diseases [R01 AI36178, R01 AI40085]
- [K08 AI081754-01]
The design of vaccines against viral disease has evolved considerably over the past 50 years. Live attenuated viruses ( LAVs)-those created by passaging a virus in cultured cells-have proven to be an effective means for preventing many viral diseases, including smallpox, polio, measles, mumps and yellow fever. Even so, empirical attenuation is unreliable in some cases and LAVs pose several safety issues. Although inactivated viruses and subunit vaccines alleviate many of these concerns, they have in general been less efficacious than their LAV counterparts. Advances in molecular virology-creating deleterious gene mutations, altering replication fidelity, deoptimizing codons and exerting control by microRNAs or zinc finger nucleases-are providing new ways of controlling viral replication and virulence and renewing interest in LAV vaccines. Whereas these rationally attenuated viruses may lead to a new generation of safer, more widely applicable LAV vaccines, each approach requires further testing before progression to human testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据